乙型肝炎病毒（HBV）感染仍然是严重威胁人类健康的一类传染病。非酒精性脂肪性肝病（NAFLD）已成为全球最常见的慢性肝病。HBV感染并发NAFLD越来越常见。本文主要介绍HBV感染与NAFLD的相互作用,脂肪变性和抗病毒药物之间的相互作用，HBV感染合并NAFLD的预后。大多数研究表明，HBV感染可以降低NAFLD的发生率。NAFLD可以促进乙型肝炎表面抗原（HBsAg）的自发清除，但它是否影响抗病毒疗效的报道并不一致。HBV感染合并NAFLD可促进肝纤维化进展,尤其是严重脂肪变性患者。HBV感染合并NAFLD诱发HCC进展的转归仍存在争议。
Hepatitis B virus (HBV) infection is still one kind of the infectious diseases that seriously threaten human health. Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. HBV infection complicated with NAFLD is increasingly common. This review mainly describes the interaction between HBV infection and NAFLD, the interaction between steatosis and antiviral drugs, and the prognosis of HBV infection complicated with NAFLD. Most studies suggest that HBV infection may reduce the incidence of NAFLD. NAFLD can promote the spontaneous clearance of hepatitis B surface antigen (HBsAg), but whether it affects antiviral efficacy has been reported inconsistently. HBV infection combined with NAFLD can promote the progression of liver fibrosis, especially in patients with severe steatosis. The outcome of HBV infection combined with NAFLD predisposing to the progression of HCC remains controversial.
PDF(Pubmed)